Scientists have found a surprising possible ally against osteoarthritis, the joint disease that can make knees ache on stairs and hips stiff after a short walk. In lab tests, tiny particles released by stem-like cells in menstrual blood helped human cartilage cells rebuild some of the material that cushions joints.
Could a monthly biological process point to a new joint therapy? Maybe, but the finding does not mean a treatment is ready for doctors’ offices. It does point to a future therapy that might use the healing messages from cells, rather than the cells themselves, to slow cartilage breakdown without major surgery.
Why osteoarthritis hurts
Osteoarthritis happens when cartilage, the smooth protective tissue at the ends of bones, wears down and loses its shock-absorbing structure. Once that cushion thins, daily movement can become painful, whether someone is climbing stairs, standing at work, or trying to sleep through joint pain.
The World Health Organization estimated that 528 million people lived with osteoarthritis in 2019, and about 60% of them were women. A 2024 global analysis estimated 606.9 million cases in 2021, a reminder that this is not a rare problem tucked away in old age.
Menstrual blood as a source
The study focused on menstrual blood-derived mesenchymal stromal cells. In simple terms, these are stem-like cells from menstrual blood that can release signals linked to repair, inflammation control, and tissue maintenance.
Those signals travel inside extracellular vesicles, tiny bubble-like packages released by cells.
Dr. Ilona Uzieliene, whose Lithuanian team included first author Gabija Kugaudaite and researchers from the Innovative Medicine Centre and Kaunas University of Technology, said, “Collecting menstrual blood is non-invasive and simple,” because it is naturally shed and does not require a bone marrow procedure.
What the team tested
Researchers collected menstrual blood from three healthy donors and isolated the stem-like cells. Then they gathered the vesicles those cells secreted, a bit like collecting sealed envelopes full of biological instructions.
They also used cartilage cells and damaged cartilage tissue discarded during joint surgery from women with osteoarthritis. That matters because the experiment did not rely only on perfect lab cells; it also tested tissue already harmed by disease.
Cartilage began rebuilding
Cartilage is not just a flat pad. It is more like a dense sponge made by chondrocytes, the main cells inside cartilage, and held together by a support network called the extracellular matrix.
In the lab, cartilage cells treated with menstrual blood vesicles made more of that support network than untreated cells. They also showed higher levels of proteoglycans, which help cartilage hold water and absorb pressure, much like a good shoe sole cushions a foot.
Damaged tissue reacted, too
The team then moved from single cells to real damaged cartilage samples. The tissue was exposed to an inflammatory signal meant to mimic the hostile environment inside an osteoarthritic joint.
When the vesicles were added, the samples lost less of their cartilage support material. That is important because osteoarthritis is not only about making new cartilage; it is also about keeping the remaining cushion from breaking apart.
Why cell-free therapy matters
A cell-free therapy would not inject living stem cells into a joint. Instead, it would use their tiny packages of biological instructions, which may be easier to dose, store, and control than whole cells.
There is still a catch. Researchers do not yet know exactly which molecules inside the vesicles are doing the useful work, and that makes safety testing and dose design essential.
Outside experts Divyesh Joshi of Yale University and Dimitrios Kouroupis of the University of Miami also urged caution about the still-open mechanism.
Not the first clue
The idea did not come out of nowhere. A 2023 laboratory study suggested that factors secreted by menstrual blood-derived cells could push bone marrow stem cells toward a cartilage-making state and protect cartilage pieces from degradation.
A 2025 review also described menstrual blood extracellular vesicles as a growing tool in regenerative medicine, with possible uses in tissue repair and disease detection. In practical terms, this new work narrows that broad promise toward one painful target: osteoarthritis.
The road ahead
The next step is not a pharmacy shelf. Researchers still need animal studies, delivery testing, manufacturing standards, and eventually human trials to see whether the effect lasts inside a moving joint.
One practical challenge is keeping the vesicles active long enough. The team is exploring biomimetic scaffolds, materials designed to imitate living tissue, so the particles could be protected and released gradually as a joint bends, bears weight, and moves through everyday life.
For now, the result is best read as a signpost, not a cure. It shows that a material often treated as waste may carry repair signals worth serious medical attention.
The main study has been published in Scientific Reports.
